Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $55.3 million.

  • Biodesix's Non-Current Assets fell 5.80% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year decrease of 5.80%. This contributed to the annual value of $57.8 million for FY2024, which is 2.78% down from last year.
  • As of Q3 2025, Biodesix's Non-Current Assets stood at $55.3 million, which was up 0.05% from $55.3 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Non-Current Assets registered a high of $59.4 million during Q4 2023, and its lowest value of $32.5 million during Q4 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $57.8 million (2024), whereas its average is $56.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first dropped by 7.00% in 2021, then skyrocketed by 50.14% in 2023.
  • Quarterly analysis of 5 years shows Biodesix's Non-Current Assets stood at $32.5 million in 2021, then climbed by 21.82% to $39.6 million in 2022, then spiked by 50.14% to $59.4 million in 2023, then fell by 2.78% to $57.8 million in 2024, then declined by 5.80% to $55.3 million in 2025.
  • Its last three reported values are $55.3 million in Q3 2025, $55.3 million for Q2 2025, and $56.6 million during Q1 2025.